13F filer · CIK 1634557
Woodford Investment Management Ltd
London, X0 · filing since Q4 2014 · last filing Jan 27, 2020
Reported value
$2.7B
+$306.9M vs prior
Positions
7
New / sold out
0 / 0
Added / reduced
6 / 1
Turnover
0.1%
buys $210.4M · sells $2.2M
Top-10 weight
100.0%
Biggest buys vs Q1 2017
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | BIOVERATIV INC | +1,186,500 | +149.9% | +$71.4M |
| Added | ABBVIE INC | +937,500 | +8.6% | +$68.0M |
| Added | GILEAD SCIENCES INC | +632,000 | +39.8% | +$44.7M |
| Added | PROTHENA CORP PLC | +294,213 | +2.6% | +$15.9M |
| Added | ALKERMES PLC | +177,449 | +2.4% | +$10.3M |
| Added | THERAVANCE BIOPHARMA INC | +1,072 | +0.0% | +$42.7K |
Biggest sells vs Q1 2017
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | BIOGEN INC | -8,143 | -2.2% | $-2.2M |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2017
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | ABBVIE INCCOMMON | 11,854,758 | $859.6M | 31.57% |
| 2 | PROTHENA CORP PLCSHS | 11,400,424 | $617.0M | 22.66% |
| 3 | ALKERMES PLCSHS | 7,647,977 | $443.4M | 16.28% |
| 4 | THERAVANCE BIOPHARMA INCCOMMON | 10,706,180 | $426.5M | 15.67% |
| 5 | GILEAD SCIENCES INCCOMMON | 2,220,100 | $157.1M | 5.77% |
| 6 | BIOVERATIV INCCOMMON | 1,977,764 | $119.0M | 4.37% |
| 7 | BIOGEN INCCOMMON | 368,645 | $100.0M | 3.67% |